ONL1204 for the Treatment of Geographic Atrophy: Phase Ib Study Evaluating Safety, Tolerability, and Efficacy.

Ophthalmol Sci · 2026 · PMC12613103 · PMID 41244992

Europe PMC DOI

hedged sentence

0.2890

closest p · 5.8× alpha

0.2890

boldest claim

The sentences

did not reach statistical significanceP = 0.289not close (p > 0.1)

The difference in slopes from the 200 μg ONL1204 treated patients during the treatment phase compared to sham-treated eyes in a paired analysis was 50% lower compared with sham-treated patients; however, this difference did not reach statistical significance ( P = 0.289).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.